Lobbying client

ISIS PHARMACEUTICALS

pharmaceutical research company

Filings
25
Filed by
1
Reported in-house
—
Reported by firms
$385,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2010 to 2016

Filings

3 filings for 2012, newest first.
Filing Filed by Amount
3rd Quarter - Termination
3rd Quarter 2012
MCDERMOTT WILL & SCHULTE LLP — reported
2nd Quarter - Report
2nd Quarter 2012
MCDERMOTT WILL & SCHULTE LLP — reported
1st Quarter - Report
1st Quarter 2012
MCDERMOTT WILL & SCHULTE LLP $10,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
MCDERMOTT WILL & SCHULTE LLP 23 $385,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Pharmacy PHA 14
Health Issues HCR 14
Medical/Disease Research/Clinical Labs MED 14

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
S. 23 112th 19
H.R. 1249 112th 19

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.